Eli Lilly acquires AtaiBeckley for $2.8 billion to expand psychedelic drug portfolio

Eli Lilly has entered into a definitive agreement to acquire AtaiBeckley for $2.8 billion in cash, marking a significant corporate entry into the experimental psychedelic pharmaceutical market. The deal, priced at a 26% premium, signals a shift in large-cap pharmaceutical strategy toward alternative mental health treatments, though the regulatory path for these substances remains complex.